1. Home
  2. MAX vs PLRX Comparison

MAX vs PLRX Comparison

Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$10.06

Market Cap

516.4M

Sector

Industrials

ML Signal

HOLD

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

81.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAX
PLRX
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
516.4M
81.1M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MAX
PLRX
Price
$10.06
$1.33
Analyst Decision
Buy
Hold
Analyst Count
5
4
Target Price
$12.70
$2.67
AVG Volume (30 Days)
440.0K
409.5K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
25.81
29.97
EPS
0.39
N/A
Revenue
$1,113,600,000.00
N/A
Revenue This Year
$13.42
N/A
Revenue Next Year
$8.16
N/A
P/E Ratio
$25.72
N/A
Revenue Growth
28.78
N/A
52 Week Low
$7.09
$1.09
52 Week High
$13.92
$1.95

Technical Indicators

Market Signals
Indicator
MAX
PLRX
Relative Strength Index (RSI) 59.85 57.52
Support Level $9.95 $1.12
Resistance Level $10.59 $1.44
Average True Range (ATR) 0.37 0.07
MACD 0.08 0.00
Stochastic Oscillator 87.58 93.75

Price Performance

Historical Comparison
MAX
PLRX

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: